A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

ClinicalTrials.gov ID: NCT05968326

Public ClinicalTrials.gov record NCT05968326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.

Study identification

NCT ID: NCT05968326
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 260 participants

Conditions and interventions

Conditions

Adenocarcinoma, Pancreatic Ductal

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 17, 2023
Primary completion: Dec 31, 2030
Completion: Dec 31, 2030
Last update posted: Sep 1, 2026

2023 – 2031

United States locations

U.S. sites: 32
U.S. states: 14
U.S. cities: 25

Facility	City	State	ZIP	Site status
USC Norris Comprehensive Cancer Center	Los Angeles	California	90033	Completed
USC Norris Cancer Center	Newport Beach	California	92663	Recruiting
University of California, San Francisco (UCSF)	San Francisco	California	94158-2350	Active, not recruiting
University of California Los Angeles	Santa Monica	California	90404	Active, not recruiting
St. Francis Hospital and Medical Center	Hartford	Connecticut	06105	Recruiting
Smilow Cancer Center	New Haven	Connecticut	06510	Withdrawn
Yale Cancer Center	New Haven	Connecticut	06520	Active, not recruiting
Smilow Cancer Hospital Care Center at Trumbull	Trumbull	Connecticut	06611	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	60611	Recruiting
Indiana University Health Melvin & Bren Simon Cancer Center	Indianapolis	Indiana	46202	Active, not recruiting
University of Kentucky Medical Center	Lexington	Kentucky	40536	Recruiting
Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center	Boston	Massachusetts	02114-2621	Active, not recruiting
Boston Medical Center (BMC) - Cancer Care Center	Boston	Massachusetts	02118	Active, not recruiting
Henry Ford Health System	Detroit	Michigan	48202-2610	Active, not recruiting
University of Nebraska	Omaha	Nebraska	68198-5300	Active, not recruiting
Memorial Sloan Kettering Cancer Center Basking Ridge	Basking Ridge	New Jersey	07920	Active, not recruiting
Memorial Sloan Kettering Cancer Center	Middletown	New Jersey	07748	Active, not recruiting
Memorial Sloan Kettering Cancer Center at Bergen	Montvale	New Jersey	07645	Recruiting
Memorial Sloan Kettering Cancer Center - Commack	Commack	New York	11725	Active, not recruiting
Memorial Sloan Kettering Cancer Center at Westchester	Harrison	New York	10604	Recruiting
Northwell Health	Lake Success	New York	11042	Active, not recruiting
NYU Langone Health	New York	New York	10016	Withdrawn
Mount SInai Medical Center	New York	New York	10029	Recruiting
Columbia University Medical Center	New York	New York	10032	Active, not recruiting
MEETH-LHH Northwell Health Cancer Clinical Trials Office at MEETH-LHH	New York	New York	10065-7471	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Active, not recruiting
Memorial Sloan Kettering Cancer Center at Nassau	Uniondale	New York	11553	Active, not recruiting
Duke Cancer Institute	Durham	North Carolina	27710-4000	Active, not recruiting
University of Cincinnati Cancer Institute	Cincinnati	Ohio	45219	Active, not recruiting
Rhode Island Hospital	Providence	Rhode Island	02903	Active, not recruiting
Miriam Hospital	Providence	Rhode Island	02906	Recruiting
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05968326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05968326 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →